Overview

  • Product name

    anti-Golimumab ELISA Kit (Simponi®)
    See all Golimumab kits
  • Detection method

    Colorimetric
  • Sample type

    Serum, Plasma
  • Assay type

    Sandwich (qualitative)
  • Assay duration

    Multiple steps standard assay
  • Species reactivity

    Reacts with: Human
  • Product overview

    anti-Golimumab ELISA Kit (Simponi®) (ab237662) is a highly specific and sensitive kit designed for the in vitro determination of the antibody against Golimumab in biological matrices such as human serum and plasma.


    Golimumab (Simponi®) is a human immunoglobulin G1κ monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-α (TNFα). Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects.

  • Tested applications

    Suitable for: Sandwich ELISAmore details
  • Platform

    Microplate

Properties

  • Storage instructions

    Store at +4°C. Please refer to protocols.
  • Components 96 tests
    Micro ELISA Plate 1 unit
    Positive Control 1 x 0.25ml
    Negative Control 1 x 0.5ml
    Assay Buffer 1 x 12ml
    Peroxidase Conjugate 1 x 12ml
    TMB substrate 1 x 12ml
    Stop Solution 1 x 12ml
    Wash buffer (20X) 1 x 50ml
    Plate sealers 1 unit
  • Relevance

    Golimumab (Simponi®) is a human immunoglobulin G1? monoclonal antibody which is specific for pro-inflammatory cytokine, tumor necrosis factor-a (TNFa). In 2009, it was approved by FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in adult patients. Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis, including juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis patients and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased levels of TNF are also found in psoriasis (Ps) plaques. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF and prevent TNF from binding to its receptors and finally inhibits biological activity of TNF.
  • Alternative names

    • Simponi
    • tumor necrosis factor-a

Applications

Our Abpromise guarantee covers the use of ab237662 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Protocols

References

ab237662 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab237662.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up